Home > Mannkind Salary

Mannkind Salary

  • 68
  • 68
  • 69
Mannkind average salary is $80,558, median salary is $80,558 with a salary range from $73,798 to $87,318.
Mannkind salaries are collected from government agencies and companies. Each salary is associated with a real job position. Mannkind salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
73,798
Average
80,558
Median
80,558
High
87,318
Total 2 Mannkind Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Physical Therapist 73,798-73,798 Oneonta, NY, 13820 2010 Mannkind Physical Therapist Salaries (1)
Mannkind Oneonta, NY Salaries
Speech-language Pathologist 87,318-87,318 Brooklyn, NY, 11201 2010 Mannkind Speech-language Pathologist Salaries (1)
Mannkind Brooklyn, NY Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Mannkind salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Mannkind Jobs
Director, National Accounts - MannKind Market Access
Mannkind - ,
Area Business Manager
Mannkind - The Woodlands, TX
Area Business Manager
Mannkind - Houston, TX
Area Business Manager
Mannkind - Denver, CO
See more Mannkind Jobs»
Search All Jobs

JobsOpenHiring – Find open jobs faster
Mannkind... Information
  • MannKind Corporation
  • Industry: Biotech/Healthcare
  • City: Valencia, CA
  • MannKind is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory, and autoimmune diseases. Our lead product, the Technosphere? Insulin System, which is currently in Phase IIb clinical trials for the treatment of diabetes, consists of our dry-powder Technosphere? formulation of insulin and our MedTone inhaler through which the powder is inhaled into the deep lung. We believe the performance characteristics, convenience and ease of use of our proprietary Technosphere? Insulin System have the potential to change the way diabetes is treated. Our Technosphere? research activities are complemented by additional